Clinical trials: Paresis
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
The purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55.
- Trial name
- NCT07429240
- Testing
- PBGENE-DMD (IV)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Mitochondrial Myopathies, Mitochondrial Pathology
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary…
- Conditions
- Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases
- Trial name
- NuPower (NCT05162768)
- Testing
- Elamipretide
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Stealth BioTherapeutics Inc.
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Thymidine Kinase 2 Deficiency
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)
This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (TK2d).
- Trial name
- NCT04581733
- Testing
- MT1621
- Sponsor
- Zogenix MDS, Inc.
Muscle Weakness
A Study in Older Participants Who Have Fallen and Have Muscle Weakness
LY2495655 is an investigational drug being tested for muscle wasting.
- Trial name
- NCT01604408
- Testing
- LY2495655
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Pelvic Floor Disorders, Pelvic Pain
Digital Care Programs for Female Pelvic Health
The purpose of this study is to create a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs.
- Conditions
- Pelvic Floor Disorders, Pelvic Pain, Pelvic Organ Prolapse, Pelvic Floor Muscle Weakness
- Trial name
- NCT05513417
- Testing
- Bloom Pod
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Sword Health, SA
Drop Foot, Muscle Weakness
Evaluation of Usability and Human Factors in the Novus System
The Novus system intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
- Conditions
- Drop Foot, Muscle Weakness, Motor Neuron Disease, Upper
- Trial name
- NCT02738242
- Testing
- Novus system
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Bioness Neuromodulation
Cerebral Palsy, Spastic Paraplegia and Hemiparesis
Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy
1. To assess the clinical and neurophysiological efficacy of Xeomin® vs. Botox® in children with spastic equine and equinovarus foot deformation in pediatric cerebral palsy 2.
- Conditions
- Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation
- Trial name
- XEBEC (NCT02188277)
- Testing
- Xeomin, Botox®
- Where
- 3 sites in Russia
- Volunteers
- 64 people
- Sponsor
- Merz Pharmaceuticals GmbH
Muscle Strength, Muscle Weakness
Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential
This minimal risk, randomized, double-blind, placebo controlled Institutional Review Board (IRB)-approved observational study with functional measurements, will evaluate athletic performance after use of a drug- free…
- Trial name
- POWER-UP (NCT06430879)
- Testing
- VICTORY PATCH
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SuperPatch Limited LLC
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock
Primary Mitochondrial Disease
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment.
- Trial name
- FALCON (NCT05650229)
- Testing
- KL1333
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 180 people
- Sponsor
- Pharming Technologies B.V.
Myasthenia Gravis
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle…
- Trial name
- NCT02965573
- Testing
- ARGX-113
- Where
- 19 sites in United States, Belgium and 6 more
- Volunteers
- 24 people
- Sponsor
- argenx
Stroke, Upper-limb Motor Impairment
Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments
This is a multicenter, randomized, controlled clinical study evaluating the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or…
- Conditions
- Stroke, Upper-limb Motor Impairment, Hemiparesis, Spinal Cord Injury
- Trial name
- NCT07404761
- Testing
- Spatial StimelMD (SSMD), Functional Electrical Stimulation (FES)
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Motion Informatics LTD
Ischemic Stroke, Upper Extremity Paresis
A Trial of Rehabilitation Paired With VNS for Motor Function in Patients With Stroke (Repair Study)
The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) paired with rehabilitation for enhancing upper extremity motor function after ischemic stroke.
- Trial name
- NCT06722677
- Testing
- VNS, Rehabilitation
- Where
- 13 sites in China
- Volunteers
- 99 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Lower Limb, Pareses
C-BRACE Versus SCO in Community Ambulators
The purpose of this multicentric study is to assess the impact of C-BRACE on mobility, endurance, confidence, participation, satisfaction, psychosocial adjustment and quality of life in community ambulators using a Stance Control…
- Trial name
- NCT05332509
- Testing
- C-BRACE, SCO
- Where
- 18 sites in France, Germany
- Volunteers
- 38 people
- Sponsor
- Otto Bock France SNC
Cardiac Diseases, Muscular Weakness
Biomarker for Pompe Disease (BioPompe)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)
- Conditions
- Cardiac Diseases, Muscular Weakness, Hepato-splenomegaly, Lung Disease
- Trial name
- BioPompe (NCT01457443)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Ischaemic Stroke, Cerebral Infarction
Pilot Investigation of Stem Cells in Stroke Phase II Efficacy
The primary aim of this Phase II trial is to determine whether it is sufficiently likely that CTX DP treatment at a dose level of 20 million cells improves the recovery in the use of the paretic arm in acute stroke patients to…
- Conditions
- Ischaemic Stroke, Cerebral Infarction, Hemiparesis, Arm Paralysis
- Trial name
- PISCES-II (NCT02117635)
- Testing
- CTX DP
- Where
- 9 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- ReNeuron Limited
Stroke
Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke
The purpose of this study is to evaluate the effect of six intravenous (IV) infusions of magnesium chloride versus placebo in patients who have residual muscle weakness from a stroke that occurred three months to four years ago.
- Trial name
- NCT00933868
- Testing
- Magnesium Chloride
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Relox Medical, LLC
Muscle Damage, Muscle Strength
HIFEM and Radiofrequency for Muscular System Function Improvement
The goal of this clinical trial is to investigate the effect of the BTL-899M device on muscular system function in adult subjects seeking treatment for improving their muscular system function in the lower extremities.
- Conditions
- Muscle Damage, Muscle Strength, Muscle Weakness
- Trial name
- NCT06703749
- Testing
- Treatment with BTL-899M, Treatment with BTL-899M with intensities below therapeutic threshold
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.